Daewoong Pharmaceutical (069620) financial statements

+130.2%since 2013
FY2025 revenue
₩1.6T▲ +10.4%
FY2025 net income
₩195.9B▲ +691.8%
FY2025 free cash flow
−₩42.3B

Daewoong Pharmaceutical income statement

Daewoong Pharmaceutical income statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue1,570,8911,422,6831,375,329
Gross profit822,532734,168688,167
Operating income196,782147,942122,592
Pretax income191,83356,550121,999
Net income195,85624,735121,739

Daewoong Pharmaceutical balance sheet

Daewoong Pharmaceutical balance sheet
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents168,942102,950111,506
Total assets2,362,7991,976,9771,770,311
Total liabilities1,228,1441,049,993858,030
Total equity1,134,656926,985912,281
Long-term debt243,421194,4250

Daewoong Pharmaceutical cash flow statement

Daewoong Pharmaceutical cash flow statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow149,20551,492136,009
Capital expenditure-191,534-155,145-109,338
Free cash flow (derived)-42,329-103,65326,671
Dividends paid-8,075-7,741-7,278

Quarterly highlights

Quarterly highlights
KRW millionsQ2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025
Period ended30 Jun 202631 Mar 202631 Dec 202530 Sep 2025
Revenue (derived)448,464377,796397,122411,832
Operating income (derived)68,06922,20843,33756,893
Net income (derived)33,36725,90189,84046,365
Operating cash flow (derived)47,05217,21040,34857,535
Total assets2,537,5722,450,3762,362,7992,260,504

Daewoong Pharmaceutical major shareholders

Daewoong Pharmaceutical major shareholders
HolderShare of classSharesFiled
대웅61.3%7,106,23426 March 2026
국민연금공단10.2%1,179,24530 September 2025

Daewoong Pharmaceutical DART filings

Daewoong Pharmaceutical DART filings
FiledFormType
13 August 2026Semiannual ReportHalf-year report
14 May 2026Quarterly ReportQuarterly report
17 March 2026Business ReportAnnual report
13 November 2025Quarterly ReportQuarterly report
13 August 2025Semiannual ReportHalf-year report
14 May 2025Quarterly ReportQuarterly report
17 March 2025Business ReportAnnual report
13 November 2024Quarterly ReportQuarterly report

Common questions

What was Daewoong Pharmaceutical's revenue in fiscal 2025?

Daewoong Pharmaceutical reported ₩1.6 trillion in revenue for fiscal 2025, the year ended 31 December 2025, up 10.4% from fiscal 2024.

What was Daewoong Pharmaceutical's net income in fiscal 2025?

Daewoong Pharmaceutical reported net income of ₩195.9 billion for fiscal 2025, the year ended 31 December 2025, up 691.8% from fiscal 2024.

What was Daewoong Pharmaceutical's free cash flow in fiscal 2025?

Daewoong Pharmaceutical had negative free cash flow of ₩42.3 billion in fiscal 2025. Operating cash flow was ₩149.2 billion and capital expenditure was ₩191.5 billion.

What were Daewoong Pharmaceutical's total assets at the end of fiscal 2025?

Daewoong Pharmaceutical reported total assets of ₩2.4 trillion at the end of fiscal 2025, the year ended 31 December 2025.

How much Daewoong Pharmaceutical history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.